Stem Cell Assay Market Report 2025

This Stem Cell Assay report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The stem cell assay market size has grown exponentially in recent years. It will grow from $2.36 billion in 2024 to $2.85 billion in 2025 at a compound annual growth rate (CAGR) of 20.8%. The growth in the historic period can be attributed to biotechnology advancements, drug discovery and development, regenerative medicine research, disease modeling, public and private investment.

The stem cell assay market size is expected to see exponential growth in the next few years. It will grow to $6.41 billion in 2029 at a compound annual growth rate (CAGR) of 22.4%. The growth in the forecast period can be attributed to personalized medicine and cellTherapy, organoid and tissue engineering, ai and machine learning, emerging technologies, regulatory and ethical considerations.Major trends in the forecast period include 3D cell culture models, high-throughput screening, personalized medicine, crispr-cas9 and genome editing, drug safety and toxicity testing.

The rising prevalence of chronic diseases is anticipated to drive the growth of the stem cell assay market in the future. Chronic diseases are defined as ailments or illnesses that persist for three months or longer and may worsen over time. Stem cells possess the potential to treat various diseases, including chronic conditions. They facilitate the development of new antibodies and specialized cells that aid in curing chronic diseases such as cancer. For example, in 2022, data from The World Cancer Research Fund International, a UK-based organization, indicated that there were 50,700 lung cancer cases in the United Kingdom, corresponding to a rate of 30.1 per 100,000 people. That year, 16,855 women died from lung cancer in the UK, resulting in a mortality rate of 17.4 per 100,000. Furthermore, in March 2024, data from The Government of the United Kingdom revealed that in the financial year ending 2023, slightly over 1,862,500 individuals in England, or 3% of the population, received a GP diagnosis of coronary heart disease (CHD). Consequently, the increasing prevalence of chronic diseases is propelling the growth of the stem cell assay market.

The growing healthcare sector is projected to drive the expansion of the stem cell assay market. The healthcare sector, also referred to as the healthcare industry or healthcare system, encompasses a range of organizations, institutions, professionals, and resources committed to delivering medical services, healthcare products, and support aimed at maintaining or enhancing people's health. Within this sector, stem cell assays are utilized for drug discovery and development, toxicity testing, disease modeling, and exploring developmental biology. For example, in 2022, data from the Office for National Statistics, a UK-based national statistics organization focused on epilepsy, indicated that healthcare expenditure in the UK reached approximately $354.88 billion (£283 billion), reflecting a nominal increase of 0.7% compared to 2021 spending. Therefore, the growing healthcare sector is expected to propel the growth of the stem cell assay market in the future.

A key trend gaining traction in the stem cell assay market is product innovation. Major companies in this market are introducing new products to maintain their competitive positions. For example, in May 2022, Beckman Coulter Life Sciences, a US-based healthcare company, introduced the AQUOS STEM System designed to aid in the development of hematopoietic stem cells. This system reduces hands-on time by 95%, minimizes error-prone processes by 87.5%, and shortens turnaround times, running on the AQUIOS CL Flow Cytometer that combines sample preparation and analysis in a compact platform.

Innovative technologies such as the LIVE Cell Death Assay (LCDA) are being developed by major companies in the stem cell assay market to meet the growing demand. LCDA, an automated solution for profiling cell health, death, apoptosis, and necrosis, offers 13 viability and death-related metrics. For instance, in September 2022, Nanolive SA, a Switzerland-based biotechnology company, launched LCDA, which finds applications in drug discovery, enabling the analysis of cell conditions related to health, stress, cell death, and recovery. This method employs machine learning to automatically measure and track cell well-being and the progression of cell death while distinguishing between apoptosis and necrosis.

In July 2022, Fujifilm Cellular Dynamics Inc., a US-based manufacturer of human-induced pluripotent stem cell technologies, entered into a partnership with PhenoVista Biosciences. This collaboration aims to provide drug discovery researchers with services for high content screening imaging using iPSC-derived differentiated cells, contributing to the drug discovery process. PhenoVista Biosciences, a US-based company, specializes in offering imaging-based phenotypic assay services for drug discovery using induced pluripotent stem cells (iPSCs) in screening.

Major companies operating in the stem cell assay market include Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories Inc., PerkinElmer Inc., Agilent Technologies Inc., Promega Corporation, Cell Biolabs Inc., Miltenyi Biotec GmbH, STEMCELL Technologies Inc., Bio-Techne Corporation, Charles River Laboratories International Inc., Hemogenix Inc., Lonza Group AG, Takara Bio Inc., Creative Bioarray, AAT Bioquest Inc., BPS Bioscience Inc., Enzo Life Sciences Inc., PromoCell GmbH, Biotium Inc., Geno Technology Inc., Abcam plc, ReachBio Research Labs. Inc., Sartorius AG, Eppendorf AG, Corning Incorporated, MEDIPOST Co. Ltd., Anterogen Co. Ltd., Corestemchemon Inc., Pharmicell Inc., NuVasive Inc., RTI Surgical Holdings Inc., AlloSource LifeSource Services Inc., JCR Pharmaceuticals Co. Ltd.

North America was the largest region in the stem cell assay market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the global stem cell assay industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the stem cell assay market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Stem cells are cells possessing the unique ability to self-renew and differentiate into specialized cell types, serving as the foundational elements for all living organisms. Stem cell assays are specifically designed to explore the growth of human stem cells and examine their biological activities within a controlled environment.

The primary categories within the stem cell assays market include cell viability and toxicity assays, cell apoptosis assays, cell function assays, cell identification assays, isolation and purification assays, and cell differentiation assays, among others. Cell viability and toxicity assays are employed to evaluate the physical and physiological health of cells under various conditions, such as exposure to external stimuli, chemical agents, medicinal treatments, or other factors, aiding in the determination of optimal conditions for cell culture growth. Products associated with these assays include instruments and detection kits utilized in diverse applications like regenerative medicine, therapy development, drug discovery, and clinical research. End users span government research institutes, private research institutes, and industry research.

The stem cell assay market research report is one of a series of new reports that provides stem cell assay market statistics, including stem cell assay industry global market size, regional shares, competitors with an stem cell assay market share, detailed stem cell assay market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell assay industry. This stem cell assay market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The stem cell assay market consists of sales of tetrazolium reduction assays, resazurin cell viability assays, calcein-AM cell viability assays, proliferation assays, differentiation assays, function assays, caspase assays and annexin v and cell permeability assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.